Pharvaris’ (PHVS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Pharvaris (NASDAQ:PHVS) in a report released on Tuesday morning,Benzinga reports. The firm currently has a $60.00 target price on the stock.

Several other analysts have also weighed in on PHVS. Wedbush raised their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Morgan Stanley raised their price target on Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, December 4th. Leerink Partners set a $38.00 price objective on Pharvaris in a research report on Wednesday, December 3rd. Guggenheim increased their target price on Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Finally, Oppenheimer raised their target price on Pharvaris from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pharvaris currently has a consensus rating of “Moderate Buy” and an average price target of $40.56.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $25.84 on Tuesday. The company’s fifty day moving average is $26.73 and its 200-day moving average is $24.84. Pharvaris has a 52 week low of $11.51 and a 52 week high of $29.80. The company has a market capitalization of $1.35 billion, a PE ratio of -8.05 and a beta of -2.78.

Hedge Funds Weigh In On Pharvaris

Large investors have recently made changes to their positions in the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in Pharvaris in the second quarter worth about $57,000. Geode Capital Management LLC boosted its stake in shares of Pharvaris by 41.1% in the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after purchasing an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the period. Legal & General Group Plc raised its stake in shares of Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after buying an additional 1,695 shares during the last quarter. Finally, Amundi lifted its holdings in Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after buying an additional 27,416 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.